Nanox Release Technology

Executive Summary

Nanox Release Technology is an Argentine biotechnology company specializing in nanotechnology-based drug delivery systems for controlled release of pharmaceuticals. Founded in 2015 and headquartered in Buenos Aires, the company leverages its proprietary platform to enhance the pharmacokinetics and bioavailability of small-molecule drugs, potentially reducing dosing frequency and improving patient compliance. As a platform-stage company, Nanox focuses on developing versatile delivery technologies that can be applied across multiple therapeutic areas, including oncology, chronic diseases, and central nervous system disorders. The platform uses engineered nanoparticles to encapsulate drugs and release them at a controlled rate, minimizing side effects and maximizing therapeutic efficacy. While the company remains private with no disclosed funding or valuation, its presence on biopharma databases suggests active development and potential partnerships. With a team of 50–200 employees, Nanox is positioned as an emerging player in the drug delivery space, a market with significant unmet need for improved formulation technologies. The lack of publicly available pipeline data limits visibility, but the company's focus on controlled release aligns with trends toward patient-centric and precision medicine.

Upcoming Catalysts (preview)

• Q4 2026Next financing round (Series A or B)70% success
• Q2 2027First-in-human clinical trial initiation40% success
• Q3 2026Pharmaceutical partnership or licensing deal50% success